187 results match your criteria: "Center for Blistering Diseases[Affiliation]"

Introduction: Pemphigus vulgaris (PV) is a life-threatening autoimmune mucocutaneous blistering disease. Systemic corticosteroids (CS), while life-saving, have several serious side effects. To improve treatment and prognosis, recently rituximab (RTX), a chimeric monoclonal antibody against CD20 molecule on B cells, has become popular.

View Article and Find Full Text PDF

Meta-Analysis of Mutations in or Identified in a Large Cohort of 224 Patients.

Genes (Basel)

January 2021

Institute of Human Genetics, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

The autosomal recessive congenital ichthyoses (ARCI) are a nonsyndromic group of cornification disorders that includes lamellar ichthyosis, congenital ichthyosiform erythroderma, and harlequin ichthyosis. To date mutations in ten genes have been identified to cause ARCI: , , , , , , , , , and . The main focus of this report is the mutational spectrum of the genes and , which encode the epidermal lipoxygenases arachidonate 12-lipoxygenase, i.

View Article and Find Full Text PDF

Diagnostic Utility of C4d by Direct Immunofluorescence in Bullous Pemphigoid.

Am J Dermatopathol

October 2021

Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Bullous pemphigoid (BP) is an autoimmune blistering disease that commonly affects elderly patients. Direct immunofluorescence (DIF) for immunoglobulin G (IgG) and C3c on frozen skin biopsies is the gold standard for the diagnosis of BP. In a minority of cases, IgG and/or C3c are found negative, and in these situations, there is a need for a more stable diagnostic marker of BP.

View Article and Find Full Text PDF

Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?

J Eur Acad Dermatol Venereol

April 2021

Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Background: Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic disorders characterized by fragility of the skin and mucosae, resulting in blisters and erosions. Several epidemiological studies in other populations have been carried out, reporting varying and sometimes inconclusive figures, highlighting the need for standardized epidemiological analyses in well-characterized cohorts.

Objectives: To evaluate the epidemiological data on EB in the Netherlands, extracted from the molecularly well-characterized cohort in the Dutch EB Registry.

View Article and Find Full Text PDF

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV).

J Eur Acad Dermatol Venereol

September 2020

Department of Dermatology and Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.

Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available.

View Article and Find Full Text PDF

Purpose: To assess whether a panel of serum pemphigoid autoantibody tests could be used to confirm an immunopathologic diagnosis of mucous membrane pemphigoid (MMP) in direct immunofluorescent negative (DIF-) MMP patients.

Design: Prospective cross-sectional study.

Participants: Seventy-six patients with multisite MMP with 45 matched control participants.

View Article and Find Full Text PDF

Immunoglobulin M bullous pemphigoid: An enigma.

JAAD Case Rep

June 2020

Department of Dermatology, University of Groningen, University Medical Center Groningen, Center for Blistering Diseases, Groningen, Netherlands.

View Article and Find Full Text PDF

Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.

Autoimmun Rev

March 2020

Department of Dermatology, Tufts University School of Medicine, The Center for Blistering Diseases, Boston, MA, USA. Electronic address:

Rituximab is a B cell depleting monoclonal antibody that targets the B cell-specific cell surface antigen CD20 and is currently used to treat several autoimmune diseases. The elimination of mature CD20-positive B lymphocytes committed to differentiate into autoantibody-producing plasma cells is considered to be the major effect of rituximab, that makes it a beneficial biological agent in treating autoimmune diseases. Hypogammaglobulinemia has been reported after rituximab therapy in patients with lymphoma and rheumatoid arthritis.

View Article and Find Full Text PDF

Anti-p200 Pemphigoid: A Systematic Review.

Front Immunol

September 2020

Department of Dermatology, Center for Blistering Diseases, Tufts University School of Medicine, Boston, MA, United States.

The many clinical aspects of anti-p200 pemphigoid are not well-characterized. We aimed to analyze and correlate known existing data on the epidemiological, clinical, histological, and immunological features of anti-p200 pemphigoid. We performed a review using Medline, Embase, and Web of Science databases (1900-2018).

View Article and Find Full Text PDF

Prevalence of Pemphigoid as a Potentially Unrecognized Cause of Pruritus in Nursing Home Residents.

JAMA Dermatol

December 2019

Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

This cross-sectional study of 125 residents of 7 nursing homes in the Netherlands evaluates the prevalence of pemphigoid as a potentially unrecognized cause of pruritus.

View Article and Find Full Text PDF

Treatment of pemphigus vulgaris: part 2 - emerging therapies.

Expert Rev Clin Immunol

October 2019

Department of Dermatology, Tufts Medical Center, Boston , MA , USA.

: Corticosteroids and immunosuppressive agents have been the mainstay for the treatment of pemphigus vulgaris (PV). While they have benefited patients, they have been associated with the risks of prolonged immune suppression and a high incidence of significant and catastrophic side effects. Relapses are common.

View Article and Find Full Text PDF

Treatment of pemphigus vulgaris: part 1 - current therapies.

Expert Rev Clin Immunol

October 2019

Department of Dermatology, Tufts Medical Center, Boston , MA , USA.

: While biologic agents that can be used for treating pemphigus vulgaris (PV) are increasing, themajority of the world's PV patients can afford only corticosteroids (CS) and some immunosuppressive agents (ISA). : The spectrum of side effects encountered when PV patients receive high-dose, long-term CS and ISA are presented based on total dose and duration of therapy. The steroid-sparing effect of individual ISA as documented in published studies and their clinical outcomes, in terms of duration of remissions, frequency of relapses and time to relapse, are presented, so that comparisons are possible.

View Article and Find Full Text PDF

Reply to: "Pruritus with pemphigoid autoantibodies is the tip of an iceberg".

J Am Acad Dermatol

November 2019

Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, the Netherlands.

View Article and Find Full Text PDF

Keratinocyte footprint assay discriminates antilaminin-332 pemphigoid from all other forms of pemphigoid diseases.

Br J Dermatol

February 2020

Center for Blistering Diseases, Department of Dermatology, University of Groningen, University Medical Center Groningen, PO Box 30 001, 9700 RB, Groningen, the Netherlands.

Background: Antilaminin-332 mucous membrane pemphigoid is a chronic severe pemphigoid disease characterized by autoantibodies to laminin-332. At present no commercial assay is available to demonstrate antilaminin-332 antibodies, and diagnosis relies on in-house techniques with limited sensitivities.

Objectives: In order to move, keratinocytes cultured in vitro secrete laminin-332 to attach to the culture dish.

View Article and Find Full Text PDF

Pyoderma gangrenosum (PG)-like ulcerations are a rare clinical manifestation of methylenetetrahydrofolate reductase (MTHFR) mutation. We describe a patient considered to have PG who was treated with long-term high doses of systemic corticosteroids and multiple immunosuppressive agents for several years. In spite of this continuous aggressive therapy, the lesions did not improve but continued to get worse.

View Article and Find Full Text PDF

Nonbullous pemphigoid: Insights in clinical and diagnostic findings, treatment responses, and prognosis.

J Am Acad Dermatol

August 2019

Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Background: Nonbullous pemphigoid is an under-recognized phenotype of the autoimmune bullous disease pemphigoid, characterized by the absence of blisters. Several disease aspects have not been studied previously.

Objective: To describe the characteristics of nonbullous pemphigoid.

View Article and Find Full Text PDF

Epidermolysis Bullosa Acquisita: The 2019 Update.

Front Med (Lausanne)

January 2019

Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.

Epidermolysis bullosa acquisita (EBA) is an orphan autoimmune disease. Patients with EBA suffer from chronic inflammation as well as blistering and scarring of the skin and mucous membranes. Current treatment options rely on non-specific immunosuppression, which in many cases, does not lead to a remission of treatment.

View Article and Find Full Text PDF

Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.

JAMA Dermatol

February 2019

Center for Blistering Diseases, Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Importance: A substantial number of patients with bullous pemphigoid do not develop skin blisters and may not have received the correct diagnosis. Diagnostic criteria and an optimal diagnostic strategy are needed for early recognition and trials.

Objectives: To assess the minimal requirements for diagnosis of bullous and nonbullous forms of pemphigoid and to evaluate the optimal diagnostic strategy.

View Article and Find Full Text PDF

Direct immunofluorescence (DIF) microscopy of a skin biopsy is used by physicians and pathologists to diagnose autoimmune bullous dermatoses (AIBD). This technique is the reference standard for diagnosis of AIBD, which is used worldwide in medical laboratories. For diagnosis of subepidermal AIBD (sAIBD), two different types of serrated pattern of immunodepositions can be recognized from DIF images, namely n- and u-serrated patterns.

View Article and Find Full Text PDF

KLHL24: Beyond Skin Fragility.

J Invest Dermatol

January 2019

University of Groningen, University Medical Center Groningen, Department of Dermatology, Center for Blistering Diseases, Groningen, The Netherlands. Electronic address:

KLHL24 mutations have recently been associated with epidermolysis bullosa simplex. Initial studies focused on skin fragility. However, the picture of KLHL24 mutations causing extracutaneous human disease is emerging, with dilated cardiomyopathy as a strong association.

View Article and Find Full Text PDF

Unmet Needs in Pemphigoid Diseases: An International Survey Amongst Patients, Clinicians and Researchers.

Acta Derm Venereol

February 2019

Center for Blistering Diseases, Department of Dermatology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, NL-9700 RB Groningen, The Netherlands.

View Article and Find Full Text PDF

Direct Immunofluorescence of Mechanobullous Epidermolysis Bullosa Acquisita, Porphyria Cutanea Tarda and Pseudoporphyria.

Acta Derm Venereol

January 2019

Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, Hanzeplein 1, NL-9700 RB Groningen, The Netherlands.

Article Synopsis
  • Mechanobullous epidermolysis bullosa acquisita (mEBA) shares similar blistering symptoms with other diseases like porphyria cutanea tarda (PCT) and pseudoporphyria, making diagnosis challenging.
  • A study analyzed biopsies from patients with mEBA, PCT, and pseudoporphyria to see if direct immunofluorescence could distinctly identify mEBA from the other conditions.
  • Results showed overlapping features in staining patterns, but also key differences, emphasizing the need for a comprehensive review of clinical and laboratory data for accurate diagnosis.
View Article and Find Full Text PDF